Shilpa Medicare gets USFDA’s approval for Varenicline Tablets

09 Apr 2025 Evaluate

ShilpaMedicare has received approval from U.S Food and Drug Administration (USFDA)for Varenicline Tablets, 0.5 and 1 mg. The total US market for this product isaround $203 million.

Thecompany’s product has been approved as a generic version to the innovator -Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism). VareniclineTablets are indicated for smoking cessation; it helps people to quit smoking.

ShilpaMedicare produces and exports consistently high-quality Active PharmaceuticalIngredients Fine Chemicals, intermediates, herbal products and specialitychemical products using sophisticated technology, meticulously followinginternational specifications.

Shilpa Medicare Share Price

278.00 8.30 (3.08%)
30-Jan-2026 12:35 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1591.05
Dr. Reddys Lab 1218.40
Cipla 1322.40
Zydus Lifesciences 886.15
Lupin 2141.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×